415 related articles for article (PubMed ID: 28459323)
1. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
Ramsey BW; Welsh MJ
Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
[No Abstract] [Full Text] [Related]
2. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
3. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Elborn JS; Davies J
Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
[No Abstract] [Full Text] [Related]
5. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
6. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
Casciaro R; Costa S; Dang P; Majo F; Ros M
Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
[No Abstract] [Full Text] [Related]
7. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
8. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
9. [Causal therapy is available].
Meißner T
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
[No Abstract] [Full Text] [Related]
10. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
11. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
12. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
13. Negotiations between the NHS and Vertex on access to lumacaftor and ivacaftor become protracted.
Burki TK
Lancet Respir Med; 2019 Sep; 7(9):739-740. PubMed ID: 31353281
[No Abstract] [Full Text] [Related]
14. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
15. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
16. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
17. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
[TBL] [Abstract][Full Text] [Related]
18. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
19. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
VanDevanter DR; Mayer-Hamblett N
Curr Opin Pulm Med; 2017 Nov; 23(6):530-535. PubMed ID: 28708817
[TBL] [Abstract][Full Text] [Related]
20. Tribulations and (clinical) trials in cystic fibrosis.
Cagnina RE; Sawicki GS
J Cyst Fibros; 2021 Mar; 20(2):188-190. PubMed ID: 33408059
[No Abstract] [Full Text] [Related]
[Next] [New Search]